| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 8.5 | 11.2 |
| Net income | -21.8 | -32.2 |
| EPS (diluted, $ a share) | $-0.16 | $-0.44 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -24.6% |
|---|---|
| Operating margin | -290.5% |
10-Q filed with the SEC, NASDAQ: CCCC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
C4 Therapeutics, Inc.: key numbers
- Share price
- $2.65Close, Nov 16
- Market cap
- $348M
- Shares outstanding
- 131.32MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from C4 Therapeutics, Inc.
All →C4 Therapeutics CFO Kendra Adams Sells $122K of Stock
Kendra Adams, CFO, sold 45,173 shares of C4 Therapeutics, Inc. at $2.71 a share, worth $122K in total on Nov 12, 2026. Shares held after the trade: 337,150 (-11.8%).
- Value
- $122K
- Shares
- 45,173
- Price
- $2.71
- Role
- CFO
- Holding change
- -11.8%
- Trade date
- Nov 12, 2026
C4 Therapeutics Financial Results
C4 Therapeutics reported financial results for the third quarter of 2026, highlighting clinical progress for its lead candidate cemsidomide. The company remains on track to complete enrollment for the Phase 2 MOMENTUM trial in Q1 2027 and expects initial data from multiple combination cohorts in mid-to-late 2027.
“Throughout the year, we have continued to build evidence supporting cemsidomide’s potential as a backbone therapy across the multiple myeloma treatment landscape while advancing our clinical development plan to evaluate cemsidomide in late and earlier lines of therapy.”
Andrew Hirsch, president and chief executive officer of C4 Therapeutics
“With data expected from these trials in 2027, we believe next year will be pivotal in establishing cemsidomide’s therapeutic profile and its potential to address the significant unmet need of patients with multiple myeloma across an evolving standard of care.”
Andrew Hirsch, president and chief executive officer of C4 Therapeutics
C4 Therapeutics Clinical Trial Data
C4 Therapeutics presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and preliminary Phase 1b data for cemsidomide combined with elranatamab at the 23rd International Myeloma Society Annual Meeting. The data demonstrated that cemsidomide drives T-cell activation and prevents T-cell exhaustion, supporting its potential as a combination partner for immune-based therapies in relapsed/refractory multiple myeloma. Additionally, the 75 µg dose level in the Phase 1b trial was declared safe, allowing the study to advance to dose expansion and escalation cohorts.